WallStSmart

Merck & Company Inc (MRK)vsOrganiGram Holdings Inc (OGI)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 21693% more annual revenue ($67.38B vs $309.18M). OGI leads profitability with a 28.0% profit margin vs 3.6%. OGI trades at a lower P/E of 1.9x. OGI earns a higher WallStSmart Score of 58/100 (C).

MRK

Hold

42

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

OGI

Buy

58

out of 100

Grade: C

Growth: 6.7Profit: 4.0Value: 6.7Quality: 6.0
Piotroski: 2/9Altman Z: -0.03
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-74.0%)

Margin of Safety

-74.0%

Fair Value

$84.93

Current Price

$144.52

$59.59 premium

UndervaluedFair: $84.93Overvalued

Intrinsic value data unavailable for OGI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$362.27B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

OGI5 strengths · Avg: 9.8/10
P/E RatioValuation
1.9x10/10

Attractively priced relative to earnings

Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
49.4%10/10

Revenue surging 49.4% year-over-year

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Profit MarginProfitability
28.0%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Debt/EquityHealth
1.203/10

Elevated debt levels

OGI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$117.60M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-6.8%2/10

ROE of -6.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : OGI

The strongest argument for OGI centers on P/E Ratio, Price/Book, Revenue Growth. Profitability is solid with margins at 28.0% and operating margin at -2.2%. Revenue growth of 49.4% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Bear Case : OGI

The primary concerns for OGI are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

MRK profiles as a value stock while OGI is a growth play — different risk/reward profiles.

OGI carries more volatility with a beta of 1.98 — expect wider price swings.

OGI is growing revenue faster at 49.4% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Bottom Line

OGI scores higher overall (58/100 vs 42/100), backed by strong 28.0% margins and 49.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

OrganiGram Holdings Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Organigram Holdings Inc. produces and sells cannabis and cannabis-derived products in Canada. The company is headquartered in Moncton, Canada.

Want to dig deeper into these stocks?